SILENCE THER. (SLN)

 

Latest News

Silence Therapeutics expands intellectual property estate

Silence Therapeutics has announced a significant expansion of its chemical modification patent estate, and might consider ...

Significant Expansion of Intellectual Property

RNS Number: 1978F Silence Therapeutics PLC 16 May 2017 Significant expansion of Intellectual Property (March to May 2017) 16 May 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces a signific...

Silence Therapeutics schedules AGM

Silence Therapeutics has announced that the Annual General Meeting of the Company will be held on Friday 2 June. At 1:5...

Notice of AGM and Publication of Annual Report

RNS Number: 2075E Silence Therapeutics PLC 04 May 2017 Notice of AGM and publication of Annual Report 4 May 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its annual report an...

All News

DateHeadlineSource
16-05-17Silence Therapeutics expands intellectual property estateStockMarketWire
16-05-17Significant Expansion of Intellectual PropertyRNS
04-05-17Silence Therapeutics schedules AGMStockMarketWire
04-05-17Notice of AGM and Publication of Annual ReportRNS
03-05-17Silence Therapeutics Presents New DataRNS
12-04-17Additional ListingRNS
03-04-17Grant of Share Options to DirectorsRNS
28-03-17Preliminary Results for the year to 31 Dec 2016RNS
08-03-17Notice of ResultsRNS
13-01-17Silence update on stake in Arrowhead PharmaceuticalsStockMarketWire
13-01-17Minority Stake in Arrowhead PharmaceuticalsRNS
09-01-17Silence Therapeutics acquires minority stake in ArrowheadStockMarketWire
09-01-17Acquisition of Minority Stake in ArrowheadRNS
20-12-16Silence Therapeutics notes Quark arbitration resolutionStockMarketWire
20-12-16Silence announces Quark arbitration resolutionRNS
15-11-16CRISPR/Cas9 Gene Editing DataRNS
27-09-16Broker Forecast - Canaccord Genuity issues a broker note on Silence Therapeutics PLCStockMarketWire
27-09-16Silence Therapeutics widens H1 lossStockMarketWire
27-09-16Half-year ReportRNS
22-09-16Notice of ResultsRNS
05-09-16Appointment of CSO and Non-Executive DirectorRNS
18-07-16Director/PDMR ShareholdingRNS
17-06-16Silence resolutions passed at AGMStockMarketWire
17-06-16Result of AGMRNS
01-06-16Holding(s) in CompanyRNS
24-05-16Board Changes, Advisory Board and Notice of AGMRNS
03-05-16Silence Therapeutics Plc to present at the SHARES Investor Evening in London on 19th MayStockMarketWire
19-04-16Director/PDMR ShareholdingRNS
18-04-16Director/PDMR ShareholdingRNS
18-04-16Grant of share options to Chief ExecutiveRNS
05-04-16Should You Dump AstraZeneca plc And Buy BTG plc & Silence Therapeutics plc?Motley Fool
05-04-16SLN updates on Atu027-I-02 studyStockMarketWire
05-04-16Silence Therapeutics narrows FY pretax lossStockMarketWire
05-04-16Atu027 UpdateRNS
05-04-16Final ResultsRNS
30-03-16Holding(s) in CompanyRNS
22-03-16Notice of ResultsRNS
18-01-16Board changesRNS
12-11-15Board appointmentRNS
30-10-15Licensee's drug to commence Ph 2/Ph 3 trialsRNS

RSS feeds

  • Editorial news feed for LSE:SLN Editorial
  • Regulatory news feed for LSE:SLN Regulatory